Kent Lake Capital LLC Has $4.34 Million Holdings in TransMedics Group, Inc. (NASDAQ:TMDX)

Kent Lake Capital LLC cut its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 45.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 55,000 shares of the company's stock after selling 45,000 shares during the quarter. TransMedics Group makes up 1.7% of Kent Lake Capital LLC's investment portfolio, making the stock its 25th largest position. Kent Lake Capital LLC owned about 0.17% of TransMedics Group worth $4,341,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of TMDX. Ancora Advisors LLC acquired a new position in TransMedics Group during the first quarter valued at approximately $38,000. First Horizon Advisors Inc. lifted its position in TransMedics Group by 45.1% during the first quarter. First Horizon Advisors Inc. now owns 544 shares of the company's stock valued at $41,000 after buying an additional 169 shares in the last quarter. Belpointe Asset Management LLC lifted its position in TransMedics Group by 51.6% during the first quarter. Belpointe Asset Management LLC now owns 558 shares of the company's stock valued at $42,000 after buying an additional 190 shares in the last quarter. PNC Financial Services Group Inc. lifted its position in TransMedics Group by 595.3% during the second quarter. PNC Financial Services Group Inc. now owns 598 shares of the company's stock valued at $50,000 after buying an additional 512 shares in the last quarter. Finally, Comerica Bank acquired a new position in TransMedics Group during the third quarter valued at approximately $34,000. 99.67% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on TMDX. Oppenheimer lifted their price objective on shares of TransMedics Group from $92.00 to $105.00 and gave the company an "outperform" rating in a research note on Tuesday, February 27th. JPMorgan Chase & Co. lifted their price objective on shares of TransMedics Group from $87.00 to $105.00 and gave the company an "overweight" rating in a research note on Tuesday, February 27th. Piper Sandler began coverage on shares of TransMedics Group in a research note on Thursday, March 28th. They set an "overweight" rating and a $95.00 price objective on the stock. Finally, Morgan Stanley lifted their price objective on shares of TransMedics Group from $75.00 to $95.00 and gave the company an "equal weight" rating in a research note on Wednesday, February 28th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $102.00.

TransMedics Group Stock Performance

TMDX stock traded up $7.84 during trading on Friday, hitting $85.04. 1,115,508 shares of the company's stock traded hands, compared to its average volume of 698,757. The company has a quick ratio of 8.49, a current ratio of 9.30 and a debt-to-equity ratio of 3.69. TransMedics Group, Inc. has a 52 week low of $36.42 and a 52 week high of $99.63. The stock has a fifty day moving average price of $82.25 and a two-hundred day moving average price of $70.76. The stock has a market capitalization of $2.78 billion, a price-to-earnings ratio of -110.44 and a beta of 1.99.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last announced its quarterly earnings results on Monday, February 26th. The company reported $0.12 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.22. The company had revenue of $81.20 million during the quarter, compared to the consensus estimate of $68.49 million. TransMedics Group had a negative net margin of 10.36% and a negative return on equity of 2.35%. The company's revenue for the quarter was up 158.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.21) earnings per share. As a group, equities analysts anticipate that TransMedics Group, Inc. will post -0.14 EPS for the current fiscal year.

Insider Buying and Selling

In other TransMedics Group news, CFO Stephen Gordon sold 15,000 shares of the company's stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $85.45, for a total value of $1,281,750.00. Following the completion of the sale, the chief financial officer now directly owns 13,075 shares of the company's stock, valued at approximately $1,117,258.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other TransMedics Group news, Director Edward M. Basile sold 7,157 shares of the company's stock in a transaction dated Tuesday, February 6th. The shares were sold at an average price of $86.38, for a total transaction of $618,221.66. Following the completion of the sale, the director now directly owns 8,350 shares of the company's stock, valued at $721,273. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Stephen Gordon sold 15,000 shares of the company's stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $85.45, for a total transaction of $1,281,750.00. Following the sale, the chief financial officer now directly owns 13,075 shares of the company's stock, valued at $1,117,258.75. The disclosure for this sale can be found here. Insiders sold 97,896 shares of company stock valued at $8,062,360 over the last 90 days. 6.70% of the stock is currently owned by company insiders.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.